Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
The purpose of this study is to investigate whether the Y402H polymorphism (rs1061170, a T-to-C transition at amino acid position 402) in the complement factor H (CFH) gene have a pharmacogenetics effect on the anti-vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (AMD). We performed a meta-analysis using databases including PubMed and EMBASE to find relevant studies. 13 published association studies were selected for this meta-analysis, including 2704 patients. For the CFH Y402H polymorphism, anti-VEGF treatment was much less effective in AMD patients with the CFH CC genotype (CC versus TT: odds ratio (OR) = 55, 95% confidence interval (CI), 0.31 to 0.95, P = 0.03; CC versus CT: OR = 0.60, 95% CI, 0.40 to 0.91, P = 0.02; and CC versus CT + TT: OR = 0.59, 95% CI, 0.38 to 0.90, P = 0.02, respectively). In subgroup analysis, CFH Y402H polymorphism was more likely to be a predictor of response for Caucasians (CC versus CT+TT: OR = 0.63, 95% CI, 0.42 to 0.95, P = 0.03). In conclusion, pharmacogenetics of CFH Y402H polymorphism may play a role in response to anti-VEGF treatment for neovascular AMD, especially for Caucasians.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“One study demonstrated nearly 42% of patients responding to anti-VEGF therapy had the CC allele [38], which is in line with the results obtained here.”
From Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients (2024) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, meta-analyses have reported an association between anti-VEGF treatment response in nAMD and the A69S polymorphism (rs10490924) in the ARMS2 gene,20 the Y402H polymorphism (rs1061170, a T-to-C transition at amino acid position 402) in the CFH gene,21,22 and the rs833061 polymorphism in the VEGFA gene.23”
From ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2 (2024) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“The study by Chen and colleagues concluded that anti-VEGF treatment was less effective in patients with the CC allele [38]”
From Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients (2024) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2014) · Medical Entomology and Zoology · Cited by 17,633
Complement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Complement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449
Complement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424
Comparison of two methods to detect publication bias in meta-analysis.
Peters, J. L. (2006) · JAMA · doi:10.1001/jama.295.6.676 · Cited by 2,278
A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints
Harbord, R. M., Egger, M., & Sterne, J. A. C. (2006) · Statistics in Medicine · doi:10.1002/sim.2380 · Cited by 2,267
Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961
Age-Related Macular Degeneration and Blindness due to Neovascular Maculopathy
Ferris, F. L., Fine, S. L., & Hyman, L. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040031330019 · Cited by 1,093 · cited 5×
“To the best of our knowledge, only one report conducted a meta-analysis focusing on the relationship between the CFH Y402H polymorphism and treatment response of neovascular AMD, indicating that CFH Y402H polymorphism might be associated with treatment response outcome in neovascular AMD21.”
MethodInfluentialVascular endothelial growth factor in eye disease
Penn, J. S., Madan, A., Caldwell, R. B., Bartoli, M., Caldwell, R. W., & Hartnett, M. E. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.001 · Cited by 762 · cited 1×
“Articles were considered eligible for inclusion in the meta-analysis if the studies met the following inclusion criteria: (1) evaluating the relationship between the CFH Y402H polymorphism and the response to anti-VEGF treatment for neovascular AMD, (2) Independent retrospective or prospective association study, and (…”
MethodAge-Related Macular Degeneration Is the Leading Cause of Blindness . . .
Bressler, N. M. (2004) · JAMA · doi:10.1001/jama.291.15.1900 · Cited by 684
Cited by
Genetics of age-related macular degeneration (AMD)
DeAngelis, M. M., Owen, L. A., Morrison, M. A., Morgan, D. J., Li, M., Shakoor, A., Vitale, A., Iyengar, S., Stambolian, D., Kim, I. K., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx228 · Cited by 164
VEGF regulates local inhibitory complement proteins in the eye and kidney
Keir, L. S., Firth, R., Aponik, L., Feitelberg, D., Sakimoto, S., Aguilar, E., Welsh, G. I., Richards, A., Usui, Y., Satchell, S. C., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86418 · Cited by 154
“Cells were genotyped for the CFH Y402H polymorphism (rs1061170, T1277C).”
BackgroundMethodInfluentialGenetics and genetic testing for age-related macular degeneration
Warwick, A., & Lotery, A. (2018) · Eye · doi:10.1038/eye.2017.245 · Cited by 67
Lorés‐Motta, L., Riaz, M., Grunin, M. A., Corominas, J., van Asten, F., Pauper, M., Leenders, M., Richardson, A. J., Muether, P. S., Cree, A. J., et al. (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.2019 · Cited by 45
The Utah Protocol for Postmortem Eye Phenotyping and Molecular Biochemical Analysis
Owen, L. A., Shakoor, A., Morgan, D. J., Hejazi, A. A., McEntire, M. W., Brown, J. J., Farrer, L. A., Kim, I. K., Vitale, A. T., & DeAngelis, M. M. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-24254 · Cited by 36
Metadata
- Authors
- Chen, G., Tzekov, R., Li, W., Jiang, F., Mao, S., & Tong, Y.
- Affiliations
- Quzhou City People's Hospital (CN)
- University of South Florida (US)
- Xiamen University (CN)
- Corresponding author
- Li, Wensheng
- Venue
- Scientific Reports
- Published
- 2015-09-28
- Volume
- 5
- Issue
- 1
- Pages
- 14517-14517
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4585967
- OpenAlex
- W2432967877
- Cited by
- 31
- References
- 47
- Citations by year
- 2025: 1 · 2024: 4 · 2022: 1 · 2021: 6 · 2020: 3 · 2019: 4 · 2018: 6 · 2017: 4 · 2016: 2
- FWCI
- 0.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- complement factor H, CFH Y402H polymorphism, rs1061170, neovascular age-related macular degeneration, anti-VEGF therapy, pharmacogenetics, treatment response prediction, genetic association, Caucasians
- MeSH terms
- Alleles, Codon, Genotype, Humans, Macular Degeneration, Pharmacogenetics, Visual Acuity, Odds Ratio, Treatment Outcome, Complement Factor H, Amino Acid Substitution, Angiogenesis Inhibitors, Polymorphism, Single Nucleotide, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.